On Friday, Shares of IsoRay, Inc. (NYSEMKT:ISR), declined -8.91% to $1.84.
IsoRay, declared its financial results for the quarter and nine months ended March 31, 2015. Recent publications are having a positive impact in the marketplace with new institutions seeking licenses to offer Cesium-131 treatment. While revenue raised a nominal two percent between the quarter ended March 31, 2014 and the quarter ended March 31, 2015, revenue was basically flat when comparing the nine month periods. IsoRay has a current cash balance of over $20,000,000 with no debt.
IsoRay’s administration continues to diversify its product offerings. Several new institutional based studies are in the final stages of implementation and their launch should be declared shortly. These studies involve new body sites or are designed to test new theories on how to better treat cancer patients with the hope of lessening patient side effects thus providing improved quality of life. Many of the Cesium-131 cases presently being performed outside the prostate are performed on patients that have aggressive cancers which to date have failed current standard of care options. Administration continues to believe the prostate market has bottomed out at this time. Administration continues to see slow adoption for IsoRay’s international sales efforts, with the devaluation of the Euro causing its products to become higher in price.
IsoRay has been very active in marketing its product line at numerous new venues in support of the growing number of body sites presently treated with Cesium-131. IsoRay exhibited at a number of national conventions and regional conferences and also sponsored industry leaders in formal dinner presentations noting the methods and successes of using Cesium-131 to treat specific cancer types. National meetings attended comprise the American Association of Neurological Surgeons, Society of Gynecological Oncology and The Society of Thoracic Surgeons. Isoray supported several institutional sponsored events counting Rutgers (Robert Wood Johnson)-Cancer Institute of NJ 2015 4-R Symposium and Weill Cornell Advances in Brachytherapy, An International Symposium.
IsoRay, Inc develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces Proxcelan Cesium-131 brachytherapy seeds for the treatment of prostate, lung, head and neck, colorectal, brain, pelvic/abdominal, and gynecological cancers, in addition to ocular melanoma.
Shares of Wal-Mart Stores Inc. (NYSE:WMT), declined -0.33% to $75.86, during its last trading session.
Wal-Mart Stores, assists people around the world save money and live better - anytime and anywhere - in retail stores, online, and through their mobile devices. Each week, nearly 260 million customers and members visit our 11,489 stores under 72 banners in 27 countries and e-commerce websites in 11 countries. With fiscal year 2015 revenue of $485.7 billion, Walmart employs about 2.2 million associates worldwide. Walmart continues to be a leader in sustainability, corporate philanthropy and employment opportunity.
Wal-Mart Stores, Inc. operates retail stores in various formats worldwide. The company operates through three segments: Walmart U.S., Walmart International, and Sam’s Club. It operates discount stores, supermarkets, supercenters, hypermarkets, warehouse clubs, cash and carry stores, home improvement stores, specialty electronics stores, restaurants, apparel stores, drug stores, and convenience stores, in addition to retail Websites, such as walmart.com and samsclub.com.
At the end of Friday’s trade, Shares of Baidu, Inc. (NASDAQ:BIDU), gained 1.83% to $203.80.
Baidu, declared its unaudited financial results for the first quarter ended March 31, 2015.
First Quarter 2015 Highlights
- Total revenues in the first quarter of 2015 were RMB12.725 billion ($2.053 billion), a 34.0% enhance from the corresponding period in 2014. Mobile revenue represented 50% of total revenue for the first quarter of 2015, up from 42% in the fourth quarter of 2014.
- Operating profit in the first quarter of 2015 was RMB2.155 billion ($347.7 million), a 9.2% decrease from the corresponding period in 2014.
- Net income attributable to Baidu in the first quarter of 2015 was RMB2.449 billion ($395.1 million), a 3.4% decrease from the corresponding period in 2014. Diluted earnings attributable to Baidu per ADS for the first quarter of 2015 were RMB6.76 ($1.09); diluted earnings attributable to Baidu per ADS not taking into account share-based compensation expenses (non-GAAP) for the first quarter of 2015 were RMB7.58 ($1.22).
Baidu, Inc. provides Internet search services in China and internationally. It offers Chinese language search platform on its Baidu.com Website that enables users to find relevant information online, counting Web pages, news, images, documents, and multimedia files through links offered on its Website; and international products and services to users in other countries.
Finally, MetLife, Inc. (NYSE:MET), ended its last trade with -0.67% loss, and closed at $53.23.
MetLife, declared that it has declared second quarter 2015 dividends of $0.2555555 per share on the company’s floating rate non-cumulative preferred stock, Series A (NYSE: METPrA), and $0.4062500 per share on the company’s 6.50% non-cumulative preferred stock, Series B (NYSE: METPrB). Both dividends are payable June 15, 2015, to shareholders of record as of May 31, 2015.
MetLife, Inc. provides life insurance, annuities, employee benefits, and asset administration products in the United States, Japan, Latin America, Asia, Europe, and the Middle East. It operates in six segments: Retail; Group, Voluntary & Worksite Benefits; Corporate Benefit Funding; Latin America; Asia; and Europe, the Middle East and Africa.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
